Pharsight

Foldrx Pharms patents expiration

1. Vyndamax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

US9770441 FOLDRX PHARMS Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Aug, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS ingredient

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage

VYNDAMAX family patents

Family Patents

2. Vyndaqel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168663 FOLDRX PHARMS Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
Dec, 2023

(3 months ago)

US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653119 FOLDRX PHARMS Methods for treating transthyretin amyloid diseases
Dec, 2023

(3 months ago)

US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage

VYNDAQEL family patents

Family Patents